Molly M Jeffery1, Jonathan W Inselman2, Jacob T Maddux3, Regina W Lam4, Nilay D Shah5, Matthew A Rank6. 1. Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. 2. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minn. 3. Department of Medicine, Mayo Clinic, Phoenix, Ariz. 4. Mayo Clinic Alix School of Medicine, Scottsdale, Ariz. 5. Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minn; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minn; OptumLabs, Cambridge, Mass. 6. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minn; Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic, Scottsdale, Ariz; Division of Pulmonology, Phoenix Children's Hospital, Phoenix, Ariz. Electronic address: Rank.matthew@mayo.edu.
Abstract
BACKGROUND: There is limited information about outcomes associated with stopping asthma biologics. OBJECTIVE: To compare outcomes in people who stopped or continued asthma biologics. METHODS: We identified a cohort of people with asthma who stopped or continued asthma biologics in the Optum Labs Database Warehouse, using a propensity matching method for case and control groups with the variables of age, sex, race, region, insurance, income, specialist access, Charlson comorbidity, specific medical conditions, pre-index exacerbation count, pre-index rescue inhaler pharmacy fills, and pre-index inhaled corticosteroid with or without long-acting β-agonist pharmacy fills. Primary outcome used to assess failure of stopping was an increase of 50% or more in the asthma exacerbation rate in the 6 months after discontinuing the biologic compared with the 6-month period before biologic initiation. RESULTS: Among a cohort of 4960 asthma biologic users, 1249 were observed to stop use after 6 to 12 months of use. We identified a matched cohort of 1247 stoppers and 1247 people who continued biologic use for at least 18 months. In the first 6 months after stopping or sham stopping, 10.2% of stoppers and 9.5% of continuers had an increase of 50% or more in asthma exacerbations. We found a similar adjusted odds of failing among stoppers and continuers (odds ratio = 1.085; 95% confidence interval, 0.833-1.413). CONCLUSIONS: An increase in asthma exacerbations is infrequently observed in people who stopped asthma biologics and was observed at similar rates as in matched controls who continued asthma biologics.
BACKGROUND: There is limited information about outcomes associated with stopping asthma biologics. OBJECTIVE: To compare outcomes in people who stopped or continued asthma biologics. METHODS: We identified a cohort of people with asthma who stopped or continued asthma biologics in the Optum Labs Database Warehouse, using a propensity matching method for case and control groups with the variables of age, sex, race, region, insurance, income, specialist access, Charlson comorbidity, specific medical conditions, pre-index exacerbation count, pre-index rescue inhaler pharmacy fills, and pre-index inhaled corticosteroid with or without long-acting β-agonist pharmacy fills. Primary outcome used to assess failure of stopping was an increase of 50% or more in the asthma exacerbation rate in the 6 months after discontinuing the biologic compared with the 6-month period before biologic initiation. RESULTS: Among a cohort of 4960 asthma biologic users, 1249 were observed to stop use after 6 to 12 months of use. We identified a matched cohort of 1247 stoppers and 1247 people who continued biologic use for at least 18 months. In the first 6 months after stopping or sham stopping, 10.2% of stoppers and 9.5% of continuers had an increase of 50% or more in asthma exacerbations. We found a similar adjusted odds of failing among stoppers and continuers (odds ratio = 1.085; 95% confidence interval, 0.833-1.413). CONCLUSIONS: An increase in asthma exacerbations is infrequently observed in people who stopped asthma biologics and was observed at similar rates as in matched controls who continued asthma biologics.
Authors: Fernando Holguin; Juan Carlos Cardet; Kian Fan Chung; Sarah Diver; Diogenes S Ferreira; Anne Fitzpatrick; Mina Gaga; Liz Kellermeyer; Sandhya Khurana; Shandra Knight; Vanessa M McDonald; Rebecca L Morgan; Victor E Ortega; David Rigau; Padmaja Subbarao; Thomy Tonia; Ian M Adcock; Eugene R Bleecker; Chris Brightling; Louis-Philippe Boulet; Michael Cabana; Mario Castro; Pascal Chanez; Adnan Custovic; Ratko Djukanovic; Urs Frey; Betty Frankemölle; Peter Gibson; Dominique Hamerlijnck; Nizar Jarjour; Satoshi Konno; Huahao Shen; Cathy Vitary; Andy Bush Journal: Eur Respir J Date: 2020-01-02 Impact factor: 16.671
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983